HER2+ Breast Cancer | Specialty

The OncLive Neoadjuvant HER2+ Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with HER2-positive breast cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances in both the localized and metastatic settings, and ongoing research in HER2-positive breast cancer.

TQB2930 Plus Chemo Drives Responses in Pretreated HER2+ Metastatic Breast Cancer

July 23rd 2025

The novel bispecific antibody TQB2930 plus chemotherapy elicited responses in heavily pretreated HER2-positive breast cancer.

Pooled Trial Data Highlight Potential of a Novel Biparatopic ADC in Heavily Pretreated HER2+ Breast Cancer

July 19th 2025

JSKN003 demonstrated tolerability and antitumor activity in heavily pretreated HER2-positive breast cancer.

Dr Hamilton on Unmet Needs for Brain Metastases in HER2+ Metastatic Breast Cancer

July 17th 2025

Erika P. Hamilton, MD, highlights the unmet needs regarding treatment for brain metastases in HER2-positive metastatic breast cancer.

FDA Grants Breakthrough Therapy Designation to Frontline T-DXd Plus Pertuzumab in HER2+ Metastatic Breast Cancer

July 17th 2025

The FDA granted breakthrough therapy designation to first-line trastuzumab deruxtecan plus pertuzumab in HER2-positive metastatic breast cancer.

Biopsy-Guided Approach Enables Surgery Omission After pCR in HER2+ and Triple-Negative Breast Cancer: With Henry M. Kuerer, MD, PhD, FACS, CMQ

July 15th 2025

Dr Kuerer discusses the potential to omit surgery in patients with HER2-positive or triple-negative breast cancer who have pCR after neoadjuvant therapy.

Dr McArthur on Monitoring for ILD When Administering T-DXd in HER2+ Breast Cancer

July 15th 2025

Heather McArthur, MD, discusses monitoring strategies for interstitial lung disease in patients with HER2-positive breast cancer treated with trastuzumab deruxtecan.

Paulus on Accelerating Clinical Development With Real-World Data in HER2+ Breast Cancer

July 11th 2025

Jessica Paulus, ScD, discusses using real-world data to add an external control arm to a study of tucatinib plus liposomal doxorubicin in HER2+ breast cancer.

Dr Tarantino on the Role of ADCs in HER2+ Breast Cancer

July 11th 2025

Paolo Tarantino, MD, details the role of ADCs in HER2-positive breast cancer, along with unmet needs that persist.

HER2DX Assay Predicts pCR Following Neoadjuvant THP in HER2+ Breast Cancer

July 10th 2025

HER2DX genomic scoring predicted pCR after neoadjuvant THP in a high-risk subgroup of patients with HER2-positive early breast cancer.

Expert Investigators Highlight Cross-Cancer Updates for Fellows From the 2025 AACR Annual Meeting

July 1st 2025

Experts in the fields of lung, head and neck, HER2+ breast, and hematologic cancers discuss notable updates for fellows from the 2025 AACR Annual Meeting.

Gedatolisib Displays Early Efficacy in mCRPC and Pretreated HER2+ Breast Cancer

June 30th 2025

Gedatolisib generated clinical activity in metastatic castration-resistant prostate cancer and HER2-positive breast cancer.

KN026 With KN046 Shows Durable Responses in Pretreated HER2+ Breast Cancer

June 30th 2025

Treatment with KN026 plus KN046 demonstrated durable responses and a manageable safety profile in previously treated HER2-positive breast cancer.

Novel ADC IBI354 Drives Responses in Pretreated HER2+ Advanced Breast Cancer

June 28th 2025

IBI354 continued to demonstrate tolerability and was active in pretreated, HER2-positive advanced breast cancer.

Dr Mouabbi on Developing Consensus Around Treatment De-Escalation in HER2+ Breast Cancer Following pCR

June 27th 2025

Jason A. Mouabbi, MD, discusses the importance of achieving consensus for integrating CompassHER2-pCR data into early-stage HER2+ breast cancer management.

TQB2102 Generates Antitumor Activity in Pretreated HER2-Low Breast Cancer

June 27th 2025

The bispecific antibody-drug conjugate TQB2102 was safe and active in pretreated, recurrent or metastatic, HER2-positive breast cancer.

Ongoing Trials Aim to Remove Carboplatin from TCHP and Reduce Treatment Cycles in HER2+ Breast Cancer

June 26th 2025

As the HER2-positive breast cancer landscape continues to evolve, the omission of carboplatin in TCHP could drive significant change.

Dr Isaacs on Establishing Consensus on DESTINY-Breast09 Data in HER2+ Metastatic Breast Cancer

June 25th 2025

Claudine Isaacs, MD, discusses how to integrate data from the phase 3 DESTINY-Breast09 trial into the HER2-positive metastatic breast cancer paradigm.

Skipping Surgery in Early HER2+ Breast Cancer or TNBC? Phase 2 Trial Data Highlight Feasibility of Selective Omission

June 24th 2025

Henry Kuerer, MD, PhD, discusses considerations for the selective omission of surgery in HER2-positive breast cancer or triple-negative breast cancer.

Paulus on the Rationale for Utilizing an External Control Arm in a Single-Arm HER2+ Breast Cancer Trial

June 23rd 2025

Jessica Paulus, ScD, explains the rationale for utilizing an external control arm in a single-arm phase 2 HER2-positive metastatic breast cancer trial.

Dr Tarantino on the Evolving Role of THP in HER2+ Metastatic Breast Cancer

June 19th 2025

Paolo Tarantino, MD, discusses the evolving role of trastuzumab plus pertuzumab and chemotherapy in HER2-positive breast cancer after DESTINY-Breast09.